Transfer of Distribution Rights for SSRI "Luvox® Tablets"

TOKYO, June 21, 2011 ─ Astellas Pharma Inc. (“Astellas”; Tokyo:4503) and Abbott Japan Co., Ltd. (“Abbott”) today announced that Astellas will transfer the rights to distribute the selective serotonin reuptake inhibitor (SSRI) Luvox® Tablets (generic name: fluvoxamine maleate) to Abbott effective on April 1, 2012. This transfer of distribution rights is taking place based on the expiration of the contract. Astellas will continue the distribution and promotion until March 31, 2012. The impact from this agreement on Astellas’ financial forecast on the current fiscal year (from April 1, 2011 to March 31, 2012) will be immaterial. ### Transfer of Distribution Rights for SSRI "Luvox® Tablets" (pdf 39KB) Contact the Media Relations team Communications & Investor Relations Main phone line for Media: ＋81-3244-3201 Business hours (JST) From Monday to Thursday: 8:45 am to 5:45 pm, Friday: 8:45 am to 4:00 pm (closed on Saturdays, Sundays, national holidays and company holidays)

The release as fetched from its publisher. astellas.com ↗